APA (7th ed.) Citation

Hu, J., Sutherland, C., Aponte Ribero, V., Zhu, L., Hou, X., Xia, Y., . . . Kang, Q. (2022). POSC94 Cost-Effectiveness of Risdiplam Versus Nusinersen for Treating Patients with Spinal Muscular Atrophy Type 1 in China. Value in Health, 25(1), S105. https://doi.org/10.1016/j.jval.2021.11.499

Chicago Style (17th ed.) Citation

Hu, J., CS Sutherland, V. Aponte Ribero, L. Zhu, X. Hou, Y. Xia, M. Tang, C. Jin, and Q. Kang. "POSC94 Cost-Effectiveness of Risdiplam Versus Nusinersen for Treating Patients with Spinal Muscular Atrophy Type 1 in China." Value in Health 25, no. 1 (2022): S105. https://doi.org/10.1016/j.jval.2021.11.499.

MLA (9th ed.) Citation

Hu, J., et al. "POSC94 Cost-Effectiveness of Risdiplam Versus Nusinersen for Treating Patients with Spinal Muscular Atrophy Type 1 in China." Value in Health, vol. 25, no. 1, 2022, p. S105, https://doi.org/10.1016/j.jval.2021.11.499.